PRQR

3.58

1.38% -0.05

Handel nachbörslich: 3.67 0.09 +2.51%

Proqr Therapeutics N V (PRQR)

Überblick Nachrichten Preisverlauf Optionskette Forum Prognose

Schlusskurs vom Vortag:

$3.63

Offen:

$3.7

24-Stunden-Volumen:

260.64K

Relative Volume:

0.21

Marktkapitalisierung:

$292.35M

Einnahmen:

$7.05M

Nettoeinkommen (Verlust:

$-30.43M

KGV:

-4.882

EPS:

-0.7333

Netto-Cashflow:

$21.84M

1W Leistung:

+3.77%

1M Leistung:

+83.59%

6M Leistung:

+78.11%

1J Leistung:

+195.87%

1-Tages-Spanne:

$3.4901

$3.75

1-Wochen-Bereich:

$3.37

$3.80

52-Wochen-Spanne:

$1.18

$4.62

Proqr Therapeutics N V Stock (PRQR) Company Profile

Firmenname

Proqr Therapeutics N V

Sektor

Healthcare (1182)

Branche

Biotechnology (671)

Telefon

Adresse

Mitarbeiter

157

Twitter

@proqr

Nächster Verdiensttermin

2024-08-05

Neueste SEC-Einreichungen

PRQR's Discussions on Twitter

Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-03-30	Hochstufung	JMP Securities	Mkt Perform → Mkt Outperform
2022-12-22	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2022-02-14	Herabstufung	Citigroup	Buy → Neutral
2022-02-11	Herabstufung	Raymond James	Strong Buy → Mkt Perform
2022-02-11	Herabstufung	Stifel	Buy → Hold
2022-02-01	Eingeleitet	Raymond James	Strong Buy
2021-05-03	Eingeleitet	Stifel	Buy
2021-03-25	Bestätigt	Citigroup	Buy
2020-11-03	Fortgesetzt	Cantor Fitzgerald	Overweight
2019-03-12	Bestätigt	Chardan Capital Markets	Buy
2018-12-19	Eingeleitet	RBC Capital Mkts	Outperform
2018-11-15	Eingeleitet	Citigroup	Buy
2018-09-19	Eingeleitet	Evercore ISI	Outperform
2017-09-26	Bestätigt	JMP Securities	Mkt Outperform
2016-06-20	Eingeleitet	Chardan Capital Markets	Neutral
2014-10-15	Eingeleitet	Deutsche Bank	Buy
2014-10-13	Eingeleitet	H.C. Wainwright	Buy

Alle ansehen

Proqr Therapeutics N V Aktie (PRQR) Neueste Nachrichten

Oct 30, 2024

Raymond James Upgrades ProQR Therapeutics N.V. (PRQR) - MSN

Oct 30, 2024

Oct 29, 2024

ProQR Therapeutics upgraded by Raymond James with a new price target - Quantisnow

Oct 29, 2024

ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Strong-Buy at Raymond James - MarketBeat

Oct 29, 2024

Oct 26, 2024

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement - GlobeNewswire

Oct 26, 2024

Oct 25, 2024

ProQR Announces Major Share Offering Agreement - TipRanks

Oct 25, 2024

Oct 23, 2024

There's Reason For Concern Over ProQR Therapeutics N.V.'s (NASDAQ:PRQR) Massive 118% Price Jump - Simply Wall St

Oct 23, 2024

ProQR Therapeutics drops on $75 mln equity raise as Eli Lilly pitches in - XM

Oct 23, 2024

Form 424B5 ProQR Therapeutics N.V. - StreetInsider.com

Oct 23, 2024

ProQR launches public offering to fund RNA therapy research - Investing.com India

Oct 23, 2024

Oct 22, 2024

ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement - StockTitan

Oct 22, 2024

ProQR Therapeutics announces public offering of ordinary shares - MSN

Oct 22, 2024

ProQR launches public offering to fund RNA therapy research By Investing.com - Investing.com UK

Oct 22, 2024

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares - GlobeNewswire

Oct 22, 2024

Oct 20, 2024

ProQR Therapeutics (NASDAQ:PRQR) shareholder returns have been solid, earning 231% in 1 year - Yahoo Finance

Oct 20, 2024

Oct 16, 2024

RNA-Editing Stocks Soar by Record on Wave Life’s Trial Data - Yahoo Finance

Oct 16, 2024

RNA-Editing Stocks Soar on Wave Life’s Breakthrough Trial Data - Bloomberg

Oct 16, 2024

Oct 14, 2024

Proqr Therapeutics RNA editing technology counteracts cholestatic disease - BioWorld Online

Oct 14, 2024

Oct 07, 2024

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - The Manila Times

Oct 07, 2024

ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society - GlobeNewswire Inc.

Oct 07, 2024

Oct 05, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving Average – Here’s Why - Defense World

Oct 05, 2024

ProQR Therapeutics (NASDAQ:PRQR) Stock Crosses Below Two Hundred Day Moving AverageHere's Why - MarketBeat

Oct 05, 2024

Oct 04, 2024

Investing in ProQR Therapeutics N.V (PRQR) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News

Oct 04, 2024

Oct 02, 2024

Best Momentum Stocks to Buy for October 2nd - Yahoo Finance

Oct 02, 2024

Sep 30, 2024

ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase - Investing.com India

Sep 30, 2024

ProQR Therapeutics' SWOT analysis: RNA editing firm's stock faces pivotal phase By Investing.com - Investing.com South Africa

Sep 30, 2024

Sep 27, 2024

ProQR Therapeutics (NASDAQ:PRQR) Shares Pass Below Two Hundred Day Moving Average of $1.95 - MarketBeat

Sep 27, 2024

ProQR Therapeutics (NASDAQ:PRQR) Share Price Passes Below Two Hundred Day Moving Average of $1.95 - Defense World

Sep 27, 2024

Sep 26, 2024